Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
359 Results Found
HHS outlines process, timeline for Medicare drug price negotiations
The Centers for Medicare & Medicaid Services yesterday released a memo and timeline outlining how it will approach implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026.
CMS Issues Proposed Rule for CY 2024 Medicare Advantage, Prescription Drug Plans
The Centers for Medicare & Medicaid Services (CMS) Dec. 14 released its proposed Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program for Contract Year (CY) 2024. The proposed rule would increase oversight of Medicare Advantage (MA) plans and better align them with Traditional Medicare, address access gaps in behavioral health services and further streamline prior authorization processes, supplementing a separate proposal last week.
Decision by U.S. District Judge Billy Roy Wilson Regarding the Legality of the 340B Drug Pricing Nondiscrimination Act
Pending are Plaintiff’s Motion for Summary Judgment on Preemption (Doc. No. 24), Defendant Leslie Rutledge’s Cross-Motion for Summary Judgment (Doc. No. 32), and Intervenors’ Cross-Motion for Summary Judgment on Preemption (Doc. No. 35). The parties have responded and replied.1 For the reasons set out below, Plaintiff’s motion is DENIED. Intervenors’ cross-motion is GRANTED. Defendant Leslie Rutledge’s cross-motion is DENIED as MOOT.
Mark Cuban Plots Next Move to Collaborate with Hospitals on Drug Shortages
Billionaire entrepreneur Mark Cuban had a simple mission when he established his Cost Plus Drugs venture in 2020 — to provide low-cost, high-quality pharmaceuticals to consumers.
HHS reports surge in drug prices over past year
Price increases for over 1,200 drugs exceeded inflation between July 2021 and July 2022, including many drugs used to treat cancer and other chronic conditions, the Department of Health and Human Services reported Friday.
CMS: Medicare Advantage, drug plan premiums decline for 2023
The Centers for Medicare & Medicaid Services yesterday released premium and cost-sharing information for Medicare Advantage and Part D prescription drug plans for the 2023 calendar year. CMS projects the average monthly premium for MA plans will fall by $1.52 to $18, while the average monthly premium for a basic Medicare Part D prescription drug plan will fall by 58 cents to $31.50.
Study debunks cost claim by drug makers
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study looked at 60 drugs approved by the Food and Drug Administration between 2009 and 2018.
AHA Comments to MedPAC Re: Topics to be Discussed at the Commissioner’s September Meeting
AHA comments to MedPAC regarding topics to be discussed at the commissioner’s September meeting.
Latest Morgan Health Investments Signal the Company’s Focus
Morgan Health, JPMorgan Chase’s health care venture arm, has been busy making good on its pledge to invest $250 million in health care startups to help reshape health care. The company recently invested $20 million in LetsGetChecked, which offers at-home diagnostic and genetic testing, virtual appointments and prescription drug delivery.
Fact Sheet: Advocacy Priorities for Fall 2022
America’s hospitals and health systems continue to deal with the difficult challenges of high inflation and ongoing effects of the COVID-19 pandemic. Specifically, hospitals are facing significant increases in costs of labor from workforce shortages, drugs, equipment and supplies (including food and energy costs) that are threatening their stability and ability to provide access to high quality health care services. The AHA has developed resources that hospital leaders can use to advocate on these important issues.